A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
Study Purpose
The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
Recruitment Criteria
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Interventional |
Eligible Ages | 12 Years - 75 Years |
Gender | All |
Inclusion Criteria:
- - Body weight of ≥ 40 kg at Baseline Visit for participants ≥ 12 and < 18 years of age.
- - Chronic atopic dermatitis (AD) with onset of symptoms at least 3 years prior to Baseline Visit and subject meets Hanifin and Rajka criteria.
- - Active moderate to severe atopic dermatitis defined by Eczema Area and Severity Index (EASI) ≥ 16, validated Investigator's Global Assessment (vIGA) ≥ 3, ≥ 10% of body surface area (BSA) with AD involvement, and weekly average of daily Worst Pruritus numerical rating scale (NRS) ≥ 4.
- - Subject has applied a topical emollient (moisturizer) twice daily for at least 7 days before the Baseline Visit.
- - Documented history of inadequate response to topical corticosteroids or topical calcineurin inhibitor OR documented systemic treatment for AD within 6 months prior to Baseline Visit.
Exclusion Criteria:
- - Prior exposure to any Janus kinase (JAK) inhibitor.
- - Unable or unwilling to discontinue current atopic dermatitis (AD) treatments prior to the study.
- - Requirement of prohibited medications during the study.
- - Other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of atopic dermatitis lesions.
Trial Details
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT03568318 |
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
Phase 3 |
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
AbbVie |
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
ABBVIE INC. |
Principal Investigator Affiliation | AbbVie |
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
Industry |
Overall Status | Enrolling by invitation |
Countries | Australia, Austria, Belgium, Canada, China, Czechia, France, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Netherlands, New Zealand, Norway, Puerto Rico, Slovakia, Spain, Sweden, United Kingdom, United States |
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Atopic Dermatitis |
Study Website: | View Trial Website |
This study includes a 35-day screening period, a 16-week double-blind period, a blinded extension period up to Week 260, a blinded Long-term Extension (LTE) Period after Week 260 to Week 524, and a 30-day follow-up visit. Participants who meet eligibility criteria in the Main Study will be randomly assigned in a 1:1:1 ratio to receive upadacitinib 15 mg, upadacitinib 30 mg, or placebo once daily, in combination with topical corticosteroids. Upon completion of enrollment of 810 participants in the Main Study, a supplemental study will continue to enroll adolescent participants (Adolescent Sub-study) until a total of 180 adolescent participants are enrolled in the overall study (Main Study + Adolescent Sub-study). Approximately 1000 participants from M16-045 or M18-891 and approximately 500 participants from M16-047 will have the opportunity to enroll into the blinded Long-Term Extension (LTE) period (Week 260
- - Week 524) after reaching Week 260 in their respective studies.
Arms
Placebo Comparator: Placebo / Upadacitinib + Topical Corticosteroids
Participants will receive placebo orally once a day (QD) for 16 weeks in the double-blind treatment period. At Week 16 participants will be re-randomized to receive either upadacitinib 15 mg or upadacitinib 30 mg QD up to Week 260. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52.
Experimental: Upadacitinib 15 mg QD + Topical Corticosteroids
Participants will receive upadacitinib 15 mg orally once a day for up to 260 weeks. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52.
Experimental: Upadacitinib 30 mg QD + Topical Corticosteroids
Participants will receive upadacitinib 30 mg orally once a day for up to 260 weeks. Participants will also receive concomitant topical corticosteroids following a step-down regimen through Week 52.
Experimental: Long-Term Extension
Participants who reach Week 260 in Studies M16-045, M18-891, and M16-047 will have the opportunity to roll over into the blinded LTE period of M16-047 to continue receiving the same daily dose of upadacitinib for up to Week 524.
Interventions
Drug: - Placebo
Tablets taken orally once a day
Drug: - Upadacitinib
Tablets taken orally once a day
Drug: - Topical corticosteroids (TCS)
Topical corticosteroids will be applied in a stepdown regimen, starting with medium potency once daily to areas with active lesions until lesions are clear or almost clear, or for 3 consecutive weeks, whichever is shorter; then low potency topical corticosteroids once daily. If lesions return or persist, this step-down approach will be repeated until lesion resolution or evidence of local or systemic topical corticosteroids toxicity. Recommended TCS include triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment as medium potency topical corticosteroids and hydrocortisone 1% cream as low potency topical corticosteroid.
Contact a Trial Team
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.
Status
Address
Total Skin and Beauty Derm Ctr /ID# 200548
Birmingham, Alabama, 35205
Status
Address
Clinical Research Center AL /ID# 201865
Birmingham, Alabama, 35209-6802
Status
Address
ACCEL Research Sites /ID# 213364
Birmingham, Alabama, 35218
Status
Address
Advanced Dermatology and Skin Care Centre /ID# 213550
Mobile, Alabama, 36605-3004
Status
Address
Alliance Dermatology and MOHs Center, PC /ID#200540
Phoenix, Arizona, 85032
Status
Address
Arizona Research Center, Inc. /ID# 200546
Phoenix, Arizona, 85053-4061
Status
Address
Clear Dermatology & Aesthetics Center /ID# 201257
Scottsdale, Arizona, 85255-4134
Status
Address
University of Arizona /ID# 201059
Tucson, Arizona, 85719
Status
Address
Bakersfield Derma & Skin Cance /ID# 200892
Bakersfield, California, 93309
Status
Address
Mosaic Dermatology /ID# 200553
Beverly Hills, California, 90211
Status
Address
University of California Irvine /ID# 200902
Irvine, California, 92697-1385
Status
Address
Therapeutics Clinical Research /ID# 200593
San Diego, California, 92123
Status
Address
Stanford University /ID# 200597
Stanford, California, 94305
Status
Address
Duplicate_University of Colorado Anchutz Medical Campus /ID# 202822
Aurora, Colorado, 80045-2517
Status
Address
Colorado Center for Dermatology, PLLC /ID# 203626
Centennial, Colorado, 80111-1724
Status
Address
Duplicate_Western States Clinical Research, Inc. /ID# 201702
Wheat Ridge, Colorado, 80033-2896
Status
Address
Dermatology Physicians of Connecticut /ID# 201004
Shelton, Connecticut, 06484-6211
Status
Address
Clearlyderm Dermatology /ID# 207709
Boca Raton, Florida, 33428
Status
Address
Skin Care Research, LLC /ID# 200812
Boca Raton, Florida, 33486-2269
Status
Address
Clinical Research of West Florida, Inc /ID# 203643
Clearwater, Florida, 33765
Status
Address
Florida Academic Centers Research and Education /ID# 200544
Coral Gables, Florida, 33134
Status
Address
Tory P Sullivan, MD PA /ID# 201174
North Miami Beach, Florida, 33162-4708
Status
Address
Park Avenue Dermatology, PA /ID# 201012
Orange Park, Florida, 32073
Status
Address
Precision Clinical Research /ID# 208734
Sunrise, Florida, 33351-7311
Status
Address
Advanced Clinical Research at Treasure Valley Dermatology & Skin Cancer Center /ID# 203628
Boise, Idaho, 83713
Status
Address
Northwestern University Feinberg School of Medicine /ID# 201646
Chicago, Illinois, 60611-2927
Status
Address
Northshore University Health System Dermatology Clinical Trials Unit /ID# 200556
Skokie, Illinois, 60077
Status
Address
DuPage Medical Group /ID# 202065
Wheaton, Illinois, 60189-3801
Status
Address
Deaconess Clinic Downtown /ID# 201001
Evansville, Indiana, 47713-1227
Status
Address
Indiana University /ID# 200515
Indianapolis, Indiana, 46202
Status
Address
Epiphany Dermatology of Kansas LLC /ID# 203026
Overland Park, Kansas, 66210
Status
Address
ORA, Inc. /ID# 202824
Andover, Massachusetts, 01810
Status
Address
Tufts Medical Center /ID# 200570
Boston, Massachusetts, 02111-1552
Status
Address
Beth Israel Deaconess Medical Center /ID# 200545
Boston, Massachusetts, 02215-5400
Status
Address
Clin Res Inst of Michigan, LLC /ID# 208020
Chesterfield, Michigan, 48047
Status
Address
Michigan Center for Research Company /ID# 200560
Clarkston, Michigan, 48346
Status
Address
MediSearch Clinical Trials /ID# 201006
Saint Joseph, Missouri, 64506
Status
Address
Skin Specialists, PC /ID# 200573
Omaha, Nebraska, 68144
Status
Address
Dartmouth-Hitchcock Medical Center /ID# 200918
Lebanon, New Hampshire, 03756
Status
Address
Psoriasis Treatment Center of Central New Jersey /ID# 200714
East Windsor, New Jersey, 08520
Status
Address
Juva Skin and Laser Center /ID# 200997
New York, New York, 10022-3204
Status
Address
J. Schwartz, MD, PLLC /ID# 202122
Troy, New York, 12180-2323
Status
Address
Bexley Dermatology Research /ID# 200899
Bexley, Ohio, 43209-2422
Status
Address
The Ohio State University /ID# 200542
Columbus, Ohio, 43210-1257
Status
Address
Vital Prospects Clinical Research Institute, PC /ID# 200901
Tulsa, Oklahoma, 74136-7049
Status
Address
Oregon Dermatology and Research Center /ID# 200601
Portland, Oregon, 97210
Status
Address
University of Pittsburgh MC /ID# 206057
Pittsburgh, Pennsylvania, 15260
Status
Address
Rhode Island Hospital /ID# 200566
Providence, Rhode Island, 02903
Status
Address
AAPRI Clinical Research /ID# 221134
Warwick, Rhode Island, 02886-2876
Status
Address
Rivergate Dermatology & Skin Care Center /ID# 201698
Goodlettsville, Tennessee, 37072-2301
Status
Address
Stones River Dermatology /ID# 204962
Murfreesboro, Tennessee, 37129-3194
Status
Address
Arlington Research Center, Inc /ID# 200559
Arlington, Texas, 76011
Status
Address
Center for Clinical Studies /ID# 200582
Houston, Texas, 77004
Status
Address
Progressive Clinical Research /ID# 201582
San Antonio, Texas, 78229
Status
Address
Center for Clinical Studies - Webster TX /ID# 203186
Webster, Texas, 77598
Status
Address
Advanced Clinical Research - Woseth Dermatology /ID# 213745
Salt Lake City, Utah, 84117-4209
Status
Address
Eastern Virginia Med School /ID# 200994
Norfolk, Virginia, 23507-1627
Status
Address
Dermatology Associates of Seattle /ID# 200717
Seattle, Washington, 98101
Status
Address
University of Wisconsin - Madison /ID# 204933
Madison, Wisconsin, 53715-1218
International Sites
Status
Address
St George Dermatology & Skin Cancer Centre /ID# 204788
Kogarah, New South Wales, 2217
Status
Address
Royal North Shore Hospital /ID# 204639
St Leonards, New South Wales, 2065
Status
Address
Westmead Hospital /ID# 205682
Westmead, New South Wales, 2145
Status
Address
Veracity Clinical Research /ID# 204793
Woolloongabba, Queensland, 4102
Status
Address
Fremantle Dermatology /ID# 205306
Fremantle, Western Australia, 6160
Status
Address
Ordensklinikum Linz GmbH Elisabethinen /ID# 209567
Linz, Oberoesterreich, 4010
Status
Address
Kepler Universitaetsklinikum GmbH /ID# 201075
Linz, Oberoesterreich, 4021
Status
Address
Medizinische Universitaet Innsbruck /ID# 210897
Innsbruck, Tirol, 6020
Status
Address
Medizinische Universitaet Wien /ID# 201080
Vienna, Wien, 1090
Status
Address
UZ Brussel /ID# 203557
Jette, Bruxelles-Capitale, 1090
Status
Address
UCL Saint-Luc /ID# 202028
Woluwe-Saint-Lambert, Bruxelles-Capitale, 1200
Status
Address
UZ Gent /ID# 202030
Gent, Oost-Vlaanderen, 9000
Status
Address
IMTR - Grand Hopital de Charleroi /ID# 202029
Loverval, , 6280
Status
Address
Kirk Barber Research, CA /ID# 200329
Calgary, Alberta, T2G 1B1
Status
Address
Dermatology Research Institute Inc. /ID# 200341
Calgary, Alberta, T2J 7E1
Status
Address
Alberta DermaSurgery Centre /ID# 205674
Edmonton, Alberta, T6G 1C3
Status
Address
Karma Clinical Trials /ID# 200339
St. John's, Newfoundland and Labrador, A1A 4Y3
Status
Address
Eastern Canada Cutaneous Resea /ID# 200335
Halifax, Nova Scotia, B3H 1Z2
Status
Address
Lynderm Research Inc. /ID# 200338
Markham, Ontario, L3P 1X2
Status
Address
DermEdge Research Inc. /ID# 200337
Mississauga, Ontario, L5H 1G9
Status
Address
The Centre for Clinical Trials /ID# 205404
Oakville, Ontario, L6J 7W5
Status
Address
Angela Montgomery Medicine Professional Corporation /ID# 212653
Ottawa, Ontario, K1H 7X3
Status
Address
SKIN Centre for Dermatology /ID# 200331
Peterborough, Ontario, K9J 5K2
Status
Address
The Center For Dermatology /ID# 205409
Richmond Hill, Ontario, L4B 1A5
Status
Address
Toronto Research Centre /ID# 205411
Toronto, Ontario, M3H 5Y8
Status
Address
Research Toronto /ID# 205410
Toronto, Ontario, M4W 2N4
Status
Address
XLR8 Medical Research /ID# 205405
Windsor, Ontario, N8W 1E6
Status
Address
CHU Sainte-Justine /ID# 206013
Montreal, Quebec, H3T 1C5
Status
Address
Centre de recheche dermatologique du Quebec Metropolitain /ID# 205403
Québec, Quebec, G1V 4X7
Status
Address
Dre Angelique Gagne-Henley M.D. inc. /ID# 200330
Saint-Jerome, Quebec, J7Z 7E2
Status
Address
Chinese PLA General Hospital /ID# 206786
Beijing, Beijing, 100853
Status
Address
Sun Yat-sen Memorial Hospital of Sun Yat-sen University /ID# 206728
Guangzhou, Guangdong, 510120
Status
Address
Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 206669
Wuhan, Hubei, 430022
Status
Address
The First Hospital of China Medical University /ID# 209840
Shenyang, Liaoning, 110001
Status
Address
The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 207132
Hangzhou, Zhejiang, 310006
Status
Address
The second Affiliated hospital of Zhejiang University school of Medicine /ID# 207442
Hangzhou, Zhejiang, 310009
Status
Address
Beijing Friendship Hospital /ID# 207434
Beijing, , 100032
Status
Address
Xiangya Hospital Central South University /ID# 207510
Changsha, , 410008
Status
Address
Huashan Hospital of Fudan University /ID# 207437
Shanghai, , 200040
Status
Address
Fakultni nemocnice Plzen /ID# 202044
Plzen, , 305 99
Status
Address
Duplicate_Vseobecna Fakultni Nemocnice /ID# 205248
Prague, , 128 08
Status
Address
Sanatorium profesora Arenbergera /ID# 202082
Praha, , 110 00
Status
Address
Vseobecna fakultni nemocnice v Praze /ID# 202045
Praha, , 128 08
Status
Address
Chu de Nice-Hopital L'Archet Ii /Id# 205780
Nice, Alpes-Maritimes, 06200
Status
Address
AP-HM - Hopital de la Timone /ID# 206128
Marseille CEDEX 05, Bouches-du-Rhone, 13385
Status
Address
CHRU Tours - Hopital Gatien de Clocheville /ID# 218209
Tours, Centre-Val De Loire, 37044
Status
Address
Hopital Saint-Andre /ID# 206129
Bordeaux, , 33075
Status
Address
Polyclinique Courlancy /ID# 201537
Reims, , 51100
Status
Address
Universitaetsklinik Heidelberg /ID# 202097
Heidelberg, Baden-Wuerttemberg, 69120
Status
Address
Universitaetsklinikum Frankfurt /ID# 202095
Frankfurt am Main, Hessen, 60590
Status
Address
Universitaetsklinikum Muenster /ID# 202094
Muenster, Nordrhein-Westfalen, 48149
Status
Address
CMS3 Company for Medical Study /ID# 205195
Selters, Rheinland-Pfalz, 56242
Status
Address
Universitaetsklinikum Schleswig-Holstein Campus Kiel /ID# 202256
Kiel, Schleswig-Holstein, 24105
Status
Address
Universitaetsklinikum Bonn /ID# 202092
Bonn, , 53127
Status
Address
TFS Trial Form Support GmbH /ID# 202096
Hamburg, , 20537
Status
Address
Medizinische Hochschule Hannover /ID# 202098
Hannover, , 30625
Status
Address
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz /ID# 205194
Mainz, , 55131
Status
Address
Klinikum rechts der Isar - Technische Universitaet Muenchen /ID# 202093
Munich, , 81675
Status
Address
401 GSNA - 401 Army General Hospital /ID# 211963
Athens, Attiki, 11525
Status
Address
Children's Hosp P. A. Kyriakou /ID# 217573
Athens, Attiki, 11527
Status
Address
University General Hospital Attikon /ID# 201126
Athens, Attiki, 12462
Status
Address
General Hospital Andreas Syggros /ID# 201123
Athens, Attiki, 16121
Status
Address
Papageorgiou General Hospital Thessaloniki /ID# 202392
Stavroupoli (Thessalonikis), Thessaloniki, 55536
Status
Address
Thessaloniki Hospital of Skin and Venereal Diseases /ID# 201124
Thessaloniki, , 54643
Status
Address
Prince of Wales Hospital /ID# 205152
Hong Kong, , 999077
Status
Address
Queen Mary Hospital /ID# 205146
Hong Kong, , 999077
Status
Address
Oroshazi Korhaz /ID# 203525
Oroshaza, Bekes, 5900
Status
Address
Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont /ID# 204144
Szeged, Csongrad, 6725
Status
Address
Debreceni Egyetem Klinikai Kozpont /ID# 201765
Debrecen, Hajdu-Bihar, 4032
Status
Address
Derma-B Egeszsegugyi es Szolgaltato Kft. /ID# 217866
Debrecen, , 4031
Status
Address
Allergo-Derm Bakos Kft. /ID# 205361
Szolnok, , 5000
Status
Address
St James Hospital /ID# 201118
Dublin 8, Dublin, D08 NHY1
Status
Address
South Infirmary Victoria University Hospital /ID# 201079
Cork, , T12 X23H
Status
Address
University Hospital Waterford /ID# 201253
Waterford, , X91 ER8E
Status
Address
Soroka University Medical Center /ID# 206652
Be'er Sheva, HaDarom, 8443901
Status
Address
The Chaim Sheba Medical Center /ID# 201611
Ramat Gan, Tel-Aviv, 5265601
Status
Address
Tel Aviv Sourasky Medical Center /ID# 201608
Tel Aviv-Yafo, Tel-Aviv, 6423906
Status
Address
HaEmek Medical Center /ID# 201958
Afula, , 1834111
Status
Address
Rabin Medical Center /ID# 201959
Petakh Tikva, , 4941492
Status
Address
Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica /ID# 203014
Rome, Lazio, 00168
Status
Address
Istituto Clinico Humanitas /ID# 200739
Rozzano, Milano, 20089
Status
Address
Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona /ID# 200690
Ancona, , 60126
Status
Address
A.O.U. Policlinico G. Rodolico S.Marco- Presidio G.Rodolico /ID# 200742
Catania, , 95123
Status
Address
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 200744
Milan, , 20122
Status
Address
Azienda Ospedaliera Universitaria Federico II /ID# 200751
Napoli, , 80131
Status
Address
Chukyo Hospital /ID# 202311
Nagoya-shi, Aichi, 457-8510
Status
Address
Medical Corporation Matsuo Clinic /ID# 202312
Fukuoka-shi, Fukuoka, 819-0373
Status
Address
Hiroshima University Hospital /ID# 201914
Hiroshima-shi, Hiroshima, 734-8551
Status
Address
Medical Corporation Kojinkai Sapporo Skin Clinic /ID#258665
Sapporo-shi, Hokkaido, 060-0063
Status
Address
Hiramoto skin clinic /ID# 204048
Amagasaki-shi, Hyogo, 661-0953
Status
Address
National Hospital Organization Sagamihara National Hospital /ID# 201658
Sagamihara-shi, Kanagawa, 252-0392
Status
Address
Queens Square Medical Center dermatology allergology /ID# 203850
Yokohama-shi, Kanagawa, 220-6208
Status
Address
University Hospital Kyoto Prefectural University of Medicine /ID#258604
Kyoto-shi, Kyoto, 602-8566
Status
Address
Kyoto University Hospital /ID# 201654
Kyoto-shi, Kyoto, 606-8507
Status
Address
Tohoku University Hospital /ID# 206322
Sendai-shi, Miyagi, 9808574
Status
Address
Osaka Habikino Medical Center /ID# 204243
Habikino-shi, Osaka, 583-8588
Status
Address
Jichi Medical University Hospital /ID# 201913
Shimotsuke-shi, Tochigi, 329-0498
Status
Address
Juntendo University Hospital /ID# 202888
Bunkyo-ku, Tokyo, 113-8431
Status
Address
Tokai University Hachioji Hospital /ID# 201711
Hachioji-shi, Tokyo, 192-0032
Status
Address
Maruyama Dermatology Clinic /ID# 202350
Koto-ku, Tokyo, 136-0074
Status
Address
Yamate Dermatological Clinic /ID# 202130
Shinjuku-ku, Tokyo, 1690075
Status
Address
Erasmus Medisch Centrum /ID# 202196
Rotterdam, Zuid-Holland, 3015 GD
Status
Address
Academisch Medisch Centrum /ID# 202193
Amsterdam, , 1105 AZ
Status
Address
Universitair Medisch Centrum Groningen /ID# 202195
Groningen, , 9713 GZ
Status
Address
Universitair Medisch Centrum Utrecht /ID# 202194
Utrecht, , 3584 CX
Status
Address
Clinical Trials NZ /ID# 205336
Hamilton, , 3204
Status
Address
Haukeland University Hospital /ID# 201152
Bergen, Hordaland, 5021
Status
Address
Universitetssykehuset N-Norge, Harstad /ID# 201269
Harstad, Troms, 9406
Status
Address
Universitetssykehuset N-Norge, Tromso /ID# 201270
Tromso, Troms, 9019
Status
Address
Rikshospitalet OUS HF /ID# 201271
Oslo, , 0450
Status
Address
Dr. Samuel Sanchez PSC /ID# 202002
Caguas, , 00727
Status
Address
Clinical Research Puerto Rico /ID# 203644
San Juan, , 00909
Status
Address
GCM Medical Group PSC - Hato Rey /ID# 202003
San Juan, , 00917-3104
Status
Address
Fakultna nemocnica s poliklinikou F.D. Roosevelta Banska Bystrica /ID# 204372
Banska Bystrica, , 975 17
Status
Address
Univerzitna nemocnica Martin /ID# 203851
Martin, , 036 01
Status
Address
Fakultna nemocnica s poliklinikou Nove Zamky /ID# 204240
Nove Zamky, , 940 34
Status
Address
Fakultna nemocnica s poliklinikou J.A. Reimana Presov /ID# 204373
Presov, , 081 01
Status
Address
Hospital Universitario de Puerto Real /ID# 200875
Puerto Real, Cadiz, 11510
Status
Address
Hospital General Universitario Alicante /ID# 200873
Alicante, , 03010
Status
Address
Hospital Santa Creu i Sant Pau /ID# 201325
Barcelona, , 08041
Status
Address
Hospital Universitario de la Princesa /ID# 201517
Madrid, , 28006
Status
Address
Hospital Universitario 12 de Octubre /ID# 201135
Madrid, , 28041
Status
Address
Hospital Universitario La Paz /ID# 205438
Madrid, , 28046
Status
Address
Skane University Hospital Lund /ID# 201244
Lund, Skane Lan, SE 221 41
Status
Address
Sahlgrenska University Hospital /ID# 201274
Gothenburg, Vastra Gotalands Lan, 413 46
Status
Address
Sodersjukhuset /ID# 201242
Stockholm, , 118 83
Status
Address
Karolinska University Hospital /ID# 201243
Stockholm, , 171 76
Status
Address
Barts Health NHS Trust /ID# 201044
London, London, City Of, E1 2ES
Status
Address
Guy's and St Thomas' NHS Foundation Trust /ID# 201193
London, London, City Of, SE1 9RT
Status
Address
Guy's and St Thomas' NHS Foundation Trust /ID# 204642
London, London, City Of, SE1 9RT
Status
Address
Oxford University Hospitals NHS Foundation Trust /ID# 202052
Oxford, Oxfordshire, OX3 9DU
Status
Address
NHS Tayside /ID# 202081
Dundee, Scotland, DD2 1UB
Status
Address
NHS Greater Glasgow and Clyde /ID# 201374
Glasgow, Scotland, G12 0XH
Status
Address
Leeds Teaching Hospitals NHS Trust /ID# 201106
Leeds, , LS9 7TF